Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luseogliflozin vs DPP-4 inhibitor on ambulatory blood pressure in type 2 diabetes with hypertension (Luseo-ABPM)
jRCTs011180019Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of luseogliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in average nighttime systolic blood pressure. Started Aug 2018; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on jRCTs011180019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011180019.